Compare Brown-Forman Corporation Class B (BF.B) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs TG Therapeutics Inc — how do they compare? Brown-Forman Corporation Class B trades at $27.98, while TG Therapeutics Inc trades at $49.6 (market cap $7.64B). Which is the better fit depends on your goals.
| BF.B | TGTX | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $59.06 |
52-Week Low | $22.80 | $26.94 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brown-Forman Class B (BF.B) trades at $28.03, down 0.57% on the day. The stock shows a bullish technical trend with moving averages supporting upside, while oscillators are neutral. Recent earnings have beaten expectations in three of the last four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst sentiment is mixed, with a 25% buy rating amid divided coverage.
The outlook is cautiously optimistic given earnings momentum, but risks include competitive pressures and market volatility. Investment appeal hinges on sustained profit growth, though the lack of clear valuation metrics and mixed analyst views suggest a balanced risk-reward profile for investors.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
